Trials / Completed
CompletedNCT01258673
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 263 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg\~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fimasartan/HCTZ combination | Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg |
| DRUG | Fimasartan | Fimasartan 60mg, 120mg |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-12-01
- First posted
- 2010-12-13
- Last updated
- 2012-01-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01258673. Inclusion in this directory is not an endorsement.